Please ensure Javascript is enabled for purposes of website accessibility

Why Verastem Stock Is Rising Today

By Prosper Junior Bakiny – Updated May 6, 2020 at 9:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.

Editor's Note: This article was updated to include more information about the clinical trial of VS-6766 and Defactinib.

What happened?

Shares of Verastem (VSTM -1.97%) -- a small-cap oncology-focused biotech -- were up by 10.9% as of 2:12 p.m. EDT on Monday. The company has not reported any news, though, so the reason behind that stock market rise is a bit of a mystery. However, that gain essentially recouped the stock's Friday decline.

So what

Verastem's stock has been highly volatile all year, and not just because of the coronavirus-fueled market crash. On April 27, its shares plunged by more than 40% after data from a study failed to impress investors. Specifically, in a clinical trial investigating the efficacy of Verastem's combination of VS-6766 and Defactinib as a treatment for aggressive tumors, only one of the 10 patients treated for KRAS mutant non-small cell lung cancer (NSCLC) experienced a tumor reduction. 

Cancer cell

Image Source: Getty Images.

This result was especially disappointing since investors have high hopes for Verastem's attempts to find a treatment for "KRAS mutant advanced solid tumors," which, according to the company, "are notoriously difficult to treat and quite common across solid tumors." In other words, this market presents an exciting opportunity for Verastem, and while last week's data temporarily took the wind out of the company's sails, investors may still be hopeful that Verastem's pipeline will eventually yield a successful treatment for KRAS-mutated tumors.

The same clinical trial also investigated the efficacy of the combination in six patients with KRAS mutant low-grade serous ovarian cancer (LGSOC), of which four experienced a tumor reduction.

Now what

Whether Verastem is worth buying right now depends on your risk tolerance. The company currently has just one approved product on the market: Copiktra, a treatment for leukemia. During the fourth quarter, Copiktra recorded a measly $3.6 million in revenue. Given that, Verastem's future largely hinges on its pipeline. A lot could go wrong for the company's investigational drugs, however, including regulatory roadblocks or more negative results from clinical trials. And, in the almost seven years since it peaked above $17 a share, the stock now down almost 90%. With that backdrop in mind, only investors willing to take on some risk should consider investing in this biotech stock

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Verastem, Inc. Stock Quote
Verastem, Inc.
VSTM
$0.85 (-1.97%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.